2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Myelodysplastic Syndromes
4
Lymphoma, Non-Hodgkin
4
Leukemia, Myelomonocytic, Juvenile
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Hemoglobinuria, Paroxysmal
4
Carcinoma, Hepatocellular
3
Squamous Cell Carcinoma of Head and Neck
2
Neuroblastoma
2
Neoplasms
2
Melanoma
2
Liver Diseases
2
Leukemia
2
Hodgkin Disease
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Non-Small Cell Lung Cancer
1
Prostatic Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Liver Neoplasms
1
Histiocytosis
1
Hemoglobinuria
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Cancer Pain
1
Interventions
Trastuzumab
628
Paclitaxel
577
Cyclophosphamide
555
Docetaxel
485
Capecitabine
401
Letrozole
376
Fulvestrant
327
Doxorubicin
294
Carboplatin
279
Tamoxifen
275
Anastrozole
243
exemestane
228
Radiotherapy
218
Epirubicin
211
Bevacizumab
196
palbociclib
189
pertuzumab
186
Vinorelbine
167
Lapatinib
167
Gemcitabine
166
pembrolizumab
162
Surveys and Questionnaires
138
Exercise
136
Magnetic Resonance Spectroscopy
123
Fluorouracil
119
Blood Specimen Collection
118
eribulin
117
Albumin-Bound Paclitaxel
117
Drug Therapy
111
130-nm albumin-bound paclitaxel
111
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Antibodies
×
Clear all
NCT03280563
2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2
Completed
144 enrolled
25 charts